ImmunityBio Inc IBRX 深 滬
已收盤 02-06 16:00:00 美东时间
6.05
+0.410
+7.27%
華盛通- 最 高6.075
- 今 開5.70
- 成交量 1822.80万股
- 最 低 5.6101
- 昨 收 5.64
- 總市值 59.59亿
- 52周最高 8.28
- 市盈率 靜 --
- 換手率 1.85%
- 52周最低 1.83
- 委 比 -76.56%
- 總股本 9.85亿
- 歷史最高 45.42
- 量 比 0.79
- 振 幅 8.24%
- 歷史最低 0.93
- 每 手 1
- 風險率 0.91%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ImmunityBio Launches Phase 2 Trial of Chemotherapy-Free CAR-NK Cell Therapy for Indolent Lymphomas
ImmunityBio Launches Phase 2 Trial of Chemotherapy-Free CAR-NK Cell Therapy for Indolent Lymphomas ImmunityBio, Inc. has announced the launch of ResQ215B, a Phase 2 clinical study evaluating a novel, chemotherapy-free and lymphodepletion-free combination immunotherapy for patients with indolent B-ce
02-02 20:02
美股大行评级 | 斯伦贝谢、SouthState Bank、西屋制动、特里科银行获多家大行上调目标价；苹果、meta、微软等绩前遭下调目标价
今日重点评级关注：Oppenheimer：维持Pelthos Therapeutics"跑赢大市"评级，目标价从57美元升至60美元；Small Cap Consumer Research：维持Lands' End"买入"评级，目标价从20美元升至45美元
01-27 10:02
ImmunityBio Amends Major Insider Convertible Note Agreement
An announcement from ImmunityBio ( ($IBRX) ) is now available. On January 23, 2...
01-26 20:33
ImmunityBio Amends Convertible Note to Allow Partial Debt-to-Equity Conversion
ImmunityBio Amends Convertible Note to Allow Partial Debt-to-Equity Conversion ImmunityBio Inc. announced an amendment to its $505 million convertible note with Nant Capital, allowing the noteholder to convert any portion of the debt into company shares before the note matures. No other changes to t
01-26 20:08
ImmunityBio Forms Biotech Alliance with Saudi Partners
ImmunityBio Forms Biotech Alliance with Saudi Partners ImmunityBio Inc. has taken part in the USA–Saudi Biotech Alliance Summit, marking the beginning of a new era in healthspan, immunotherapy, and global scientific partnership. This collaboration aims to advance innovative healthcare solutions and
01-26 15:54
ImmunityBio Reports Promising Survival Data for ANKTIVA Plus CAR-NK in Recurrent Glioblastoma Trial
ImmunityBio Reports Promising Survival Data for ANKTIVA Plus CAR-NK in Recurrent Glioblastoma Trial ImmunityBio Inc. has announced updated Phase 2 clinical results from the QUILT 3.078 trial (NCT06061809) evaluating a chemotherapy-free combination immunotherapy regimen, ANKTIVA® plus CAR-NK, in pati
01-26 14:52
美股大行评级 | 英特尔绩后获多家大行上调目标价；理想汽车、Mobileye、Meta、微软、甲骨文等遭下调目标价
今日重点评级关注：RBC Capital：维持Compass Pathways"跑赢大市"评级，目标价从16美元升至21美元；RBC Capital：维持GH Research"跑赢大市"评级，目标价从33美元升至40美元
01-26 14:32
Catalyst Watch: Microsoft earnings, Boeing buzz, FOMC meeting, and fintech IPOs
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Monday - January 2...
01-24 04:00
BUZZ-ImmunityBio releases early brain cancer treatment trial data; shares down
BUZZ-ImmunityBio releases early brain cancer treatment trial data; shares down ** Shares of drug developer ImmunityBio IBRX.O fall 3% to $7.13 premarket ** Co says 19 of 23 patients in its ongoing study for recurrent glioblastoma, an aggressive brain cancer, remain alive after treatment, with median
01-23 21:27
期权扫描 | 英特尔期权成交翻倍，看涨期权集体飙升最高涨850%！美光股价创新高，多张看涨期权大涨超200%
英特尔期权成交翻倍，看涨期权集体飙升最高涨850%！美光股价创新高，多张看涨期权大涨超200%；IBRX期权大异动，资金押注长期催化剂>>
01-22 15:00
